Sources

1. * Weghuber D et al (2022) "Once-weekly semaglutide in adolescents with obesity" New England Journal of Medicine

https://doi.org/10.1056/NEJMoa2208601

2. https://www.nice.org.uk/news/article/nice-recommends-new-drug-for-people-living-with-obesity

3. Wilding, J.P.H. et al. (2021) "Once-weekly semaglutide in adults with overweight or obesity" New England Journal of Medicine, 384(11)

https://doi.org/10.1056/NEJMoa2032183

4. Jastreboff, A.M. et al. (2022) "Tirzepatide Once Weekly for the Treatment of Obesity" New England Journal of Medicine, 387(3)

https://doi.org/10.1056/NEJMoa2206038

5. Wilding J.P.H et al (2022) "Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension", Diabetes, Obesity and Metabolism (24)

https://doi.org/10.1111/dom.14725

6. Davies M et al (2021), "Semaglutide 2.4mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)" The Lancet (397)

https://doi.org/10.1016/S0140-6736(21)00213-0